Biotech Targeting Alzheimer's Disease Advances Toward Phase 1
Source: Streetwise Reports
June 13, 2018 (Investorideas.com Newswire) Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.
ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), in a June 12 press release, announced "the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer's disease." Selexis SA, called a "global leader in mammalian (suspension-adapted CHO-K1) cell line generation," has signed on to manufacture the therapeutic.
Phase 1 clinical trials for PMN310 are slated to begin in the second half of 2019, according to the announcement. The drug targets toxic oligomers, which ProMIS calls a "root cause" of Alzheimer's disease.
ProMIS President and CEO Dr. Elliot Goldstein stated the company had "recently completed successful affinity maturation of PMN310, which in addition to its unique and highly selective binding profile offers increased opportunity for best in class therapy for Alzheimer's disease."
Both Goldstein and Selexis vice president Yemi Onakunle highlighted the synergy between the two companies' products. "We believe our best-in-class technology can help propel forward this best-in-class therapeutic candidate," Onakunle stated in the release.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.